Compare Stocks

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVAX Evaxion Biotech A/S	$4.22 +2.7%	$3.56	$2.82 ▼ $18.50	$22.03M	-0.02	572,925 shs	35,373 shs
INKT MiNK Therapeutics	$0.87 -4.4%	$0.96	$0.75 ▼ $3.34	$30.25M	0.13	91,714 shs	42,419 shs
PLX Protalix BioTherapeutics	$1.13 -1.7%	$1.37	$1.09 ▼ $3.55	$82.55M	0.88	330,828 shs	421,188 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVAX Evaxion Biotech A/S	+2.68%	+8.48%	+37.46%	-37.21%	-70.90%
INKT MiNK Therapeutics	-4.76%	-14.54%	+1.36%	-0.94%	-57.48%
PLX Protalix BioTherapeutics	-1.74%	-7.38%	-13.08%	-24.92%	-54.25%

New crypto project uncovers 2,050% in 65 days (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVAX Evaxion Biotech A/S	2.0952 of 5 stars	3.5	4.0	1.0	1.7	0.6
INKT MiNK Therapeutics	3.0641 of 5 stars	3.5	5.0	3.8	0.8	0.6
PLX Protalix BioTherapeutics	2.598 of 5 stars	3.5	0.0	1.1	0.0	3.1

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVAX Evaxion Biotech A/S	3.00	Buy	$11.00	160.66% Upside
INKT MiNK Therapeutics	3.00	Buy	$9.00	932.47% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$10.00	784.96% Upside

Current Analyst Ratings

Latest EVAX, PLX, and INKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2024	EVAX Evaxion Biotech A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
4/2/2024	EVAX Evaxion Biotech A/S	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00
3/21/2024	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $9.00
3/20/2024	EVAX Evaxion Biotech A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
2/12/2024	EVAX Evaxion Biotech A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVAX Evaxion Biotech A/S	$70K	314.69	N/A	N/A	($1.17) per share	-3.61
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($0.52) per share	N/A
PLX Protalix BioTherapeutics	$65.49M	1.26	$0.14 per share	8.35	$0.47 per share	2.40

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVAX Evaxion Biotech A/S	-$22.12M	-$6.76	N/A	32.46	N/A	N/A	-451.63%	-149.27%	5/29/2024 (Estimated)
INKT MiNK Therapeutics	-$22.46M	-$0.66	N/A	N/A	N/A	N/A	N/A	-220.64%	5/9/2024 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.05	22.60	1.40	N/A	12.69%	29.73%	10.17%	5/2/2024 (Estimated)

Latest EVAX, PLX, and INKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/27/2024	Q4 2023	EVAX Evaxion Biotech A/S	N/A	-$0.16	-$0.16	-$0.16	N/A	$0.07 million
3/21/2024	Q4 2023	INKT MiNK Therapeutics	-$0.15	-$0.16	-$0.01	-$0.16	N/A	N/A
3/14/2024	Q4 2023	PLX Protalix BioTherapeutics	-$0.03	-$0.07	-$0.04	-$0.07	$8.15 million	$10.49 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVAX Evaxion Biotech A/S	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVAX Evaxion Biotech A/S	N/A	1.18	1.18
INKT MiNK Therapeutics	N/A	0.32	0.32
PLX Protalix BioTherapeutics	N/A	1.54	1.12

Ownership

Institutional Ownership

Company	Institutional Ownership
EVAX Evaxion Biotech A/S	11.04%
INKT MiNK Therapeutics	2.87%
PLX Protalix BioTherapeutics	16.53%

Insider Ownership

Company	Insider Ownership
EVAX Evaxion Biotech A/S	41.64%
INKT MiNK Therapeutics	17.81%
PLX Protalix BioTherapeutics	4.97%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EVAX Evaxion Biotech A/S	63	5.22 million	3.04 million	Optionable
INKT MiNK Therapeutics	31	34.70 million	28.52 million	No Data
PLX Protalix BioTherapeutics	208	73.05 million	69.42 million	Optionable

EVAX, PLX, and INKT Headlines

Source	Headline
	Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript seekingalpha.com - March 16 at 2:19 PM
	Earnings call: Protalix BioTherapeutics reports fiscal year 2023 results uk.investing.com - March 16 at 2:19 PM
	Production cuts, geopolitical tensions drive oil rally ca.finance.yahoo.com - March 15 at 3:47 PM
	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 15 at 1:25 PM
	PLX: Elfabrio Geographic Expansion finance.yahoo.com - March 15 at 10:47 AM
	Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results finanznachrichten.de - March 14 at 8:43 AM
	Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023 finance.yahoo.com - March 14 at 8:43 AM
	Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results prnewswire.com - March 14 at 6:50 AM
	Here's what Wall Street expects from Protalix BioTherapeutics's earnings report markets.businessinsider.com - March 13 at 5:33 PM
	Earnings Preview: Protalix BioTherapeutics benzinga.com - March 13 at 5:33 PM
	Protalix Biotherapeutics, Inc. edition.cnn.com - March 9 at 1:28 PM
	Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 finance.yahoo.com - March 7 at 8:30 AM
	Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference prnewswire.com - February 23 at 6:50 AM
	PLX Mar 2024 1.500 call ca.finance.yahoo.com - February 17 at 1:05 AM
	Abeona issues update on FDA market application for pz-cel msn.com - February 2 at 7:17 AM
	Will These 3 Biotech Stocks Make Gains in 2024? entrepreneur.com - January 25 at 7:43 AM
	Protalix BioTherapeutics Inc. [PLX] Investment Appeal on the Rise knoxdaily.com - January 2 at 6:59 PM
	Protalix BioTherapeutics Issues 2024 Letter to Stockholders finance.yahoo.com - December 26 at 7:21 AM
	Protalix BioTherapeutics Stock (AMEX:PLX) Insider Trades benzinga.com - December 15 at 11:33 PM
	H.C. Wainwright reiterates Protalix BioTherapeutics Inc. (PLX) rating to a Buy knoxdaily.com - November 13 at 3:59 PM
	PLX: More Regulatory Approvals finance.yahoo.com - November 7 at 9:39 AM
	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript finance.yahoo.com - November 7 at 9:39 AM
	American Well, Protalix BioTherapeutics among healthcare movers msn.com - November 6 at 10:40 AM
	Protalix BioTherapeutics GAAP EPS of -$0.04 beats by $0.03, revenue of $10.35M beats by $2.71M msn.com - November 6 at 8:24 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Evaxion Biotech A/S

NASDAQ:EVAX

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

MiNK Therapeutics

NASDAQ:INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Protalix BioTherapeutics

NYSE:PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Carmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial